Under the agreement, Servier will pay $1.55 billion upfront, with up to an additional $1.1 billion tied to regulatory and commercial milestones.

Edgewise Therapeutics on Monday agreed to sell its muscular dystrophy drug and related business to Servier in a deal worth up to $2.65 billion, marking an expansion for the French group beyond its ...

Parent Project Muscular Dystrophy (PPMD), the leading U.S. non-profit driving Duchenne and Becker muscular dystrophy care, research, and advocacy efforts, will host its 2026 Annual Conference in ...

Individuals with rare diseases face significant challenges in obtaining disability certification and financial support in Andhra Pradesh.

Being part of the PPMD conference's Adult Advisory Committee has helped columnist Patrick Moeschen bond with those who share ...